DiaSorin The Diagnostic Specialist

Press Release

DIASORIN S.P.A., THE BOARD OF DIRECTORS APPROVES THE FULL YEAR RESULTS FOR 2010 AND RECOMMENDS THE DISTRIBUTION OF A DIVIDEND OF 0.40 EUROS PER OUTSTANDING SHARE.

2010 full year financial highlights

- Consolidated net revenues rise to 404.5 million euros, or 33.0% more than the 304.1 million euros reported in 2009;
- EBITDA grow to 167.1 million euros, for a gain of 35.2% compared with 123.6 million euros in 2009;
- EBIT rise to 145.5 million euros, up 36.7% compared with 106.4 million euros in 2009;
- Consolidated net profit increases to 90.4 million euros, or 29.1% more than in 2009;
- Consolidated net financial position positive by 33.1 million euros, compared with a positive balance of 11.2 million euros at December 31, 2009;
- The Board of Directors agreed to submit a motion to the Shareholders' Meeting convened for April 28, 2011, on the first calling, and April 29, 2011, on the second calling, recommending:
    - the approval of the annual financial statements at December 31, 2010;
    - the appropriation of net income, including the distribution of a dividend of 0.40 euros per share, outstanding at the coupon record date, with coupon record date of June 13th and payment date of June 17th.

Saluggia, March 16, 2011 – The Board of Directors of DiaSorin S.p.A., a company that operates in the global market for in vitro diagnostics, meeting under the chairmanship of Gustavo Denegri, approved a draft of the 2010 annual financial statements and the consolidated financial statements presented by Carlo Rosa, the Company's Chief Executive Officer.
The Board of Directors further agreed to convene a Shareholders' Meeting for April 28, 2011, on the first calling, and April 29, 2011, on the second calling, to approve the annual financial statements and vote on a motion recommending that the Shareholders' Meeting distribute a dividend in the amount of 0.40 euros per share, outstanding at the coupon record date, with coupon record date of June 13th and payment date of June 17th.

Key events of 2010

In 2010, the Group's research and development activities continued to contribute to the expansion of the DiaSorin product line in terms both of system platforms and available assay menus:

- New important tests, such as the Parvovirus B19, the Micoplasma (IgG and IgM) and the 1-84PTH, all specialty tests offered exclusivity by DiaSorin on CLIA technology, were launched in 2010. In addition, consistent with its commitment to innovation and to meeting the needs of laboratories and clinicians, the Group introduced the Calcitonin II Gen kit.
- In 2010, DiaSorin secured registration in China for nine new Liaison products in the clinical areas of infectious diseases and oncology, increasing to 41 test its catalog of CLIA technology products. Specifically, in the second quarter of the year, DiaSorin received from the State Food and Drug Administration (the Chinese entity with jurisdiction over approving the sale of diagnostic products) authorizations to market tests to detect the presence of Cytomegalovirus IgM, Rubella IgM and Herpes Simplex IgM, thereby becoming the only supplier in China capable of offering the complete prenatal screening panel (ToRCH IgM – Toxoplasmosis, Rubella, Cytomegalovirus, Herpes simplex virus) on fully automated CLIA technology.
- In the third quarter of 2010, DiaSorin entered into an exclusive agreement with Meridian Inc. to develop a panel of tests in the area of gastrointestinal infectious diseases, based on technology provided by Meridian, and distribute them worldwide as products available on the Liaison and Liaison XL platforms. Pursuant to this agreement, DiaSorin will enjoy exclusive distribution rights for new products develop in collaboration with Meridian, except for the United States and the United Kingdom, where Meridian will retain the right of first

refusal with regard to distribution. This collaborative relationship got under way with the development of tests to detect the *Clostridium difficile*, which is believed to be responsible for most infections contracted in hospital environments, and the *Helicobacter pylori*, which is the main cause of gastric ulcers and contributes to the development of tumors in the gastric system.

- In the fourth quarter of 2010, the Group began the gradual commercial introduction of the Liaison XL analyzer in select European countries. This system is being marketed with an assay menu that includes new HIV, HCV and HBsAg products (available only on Liaison XL), as well as the Liaison Vitamin D Total test and 13 additional endocrinology and oncology tests. The other tests available on the Liaison platform will be validated for use on the Liaison XL system in 2011.

In 2010, the Group also carried out important projects that bolstered its strategy of growth through geographic expansion and provided a base for future expansion through acquisitions:

- In the first quarter of the year, DiaSorin China and the Netherlands subsidiary of DiaSorin Belgium began direct distribution in their respective markets. DiaSorin Australia was established in July and, after purchasing the distribution rights for Australia and New Zealand from the local distributor, began direct distribution activities on August 1, 2010.
- The acquisition of the MUREX® product line from the Abbott Group was completed on June 1, 2010. The MUREX® product line, which is based on ELISA (Enzyme Linked Immunosorbent Assay) technology, consists mainly of products to diagnose HIV, HCV and HBV infections. These products, which target the blood bank market, are manufactured at two plants in the United Kingdom and South Africa that were included in the transaction. In 2009, the MUREX® product line generated revenues of about 66.7 million U.S. dollars. Trade receivables and payables were not included in the transaction, which was funded by DiaSorin entirely with internal resources, with an outlay of about 58 million U.S. dollars. In the fourth quarter of 2010, in a development related to the Murex transaction, the Company announced and implemented a restructuring plan for the Dartford production facility that affected 82 employees.

Highlights of the consolidated income statement and statement of financial position for 2010

DiaSorin reported highly positive results, continuing to outperform the market averages for its industry in 2010, a year in which the global economic continued to recover, albeit at uneven paces in the different geographic regions, hampered by fresh doubts about the sovereign-debt solvency of several euro-zone countries fueled primarily by uncertainties about the sustainability of the fiscal situation in those countries.

Differently from the results reported by other industry operators in 2010, DiaSorin was not affected by unfavorable economic conditions in its industry, achieving operating and financial results that were significantly better than those reported a year earlier and confirming the wisdom of the strategic choices implemented in the recent past.

Specifically, Group **revenues** rose to 404.5 million euros, or 33.0% more than in 2009 (28.9% at constant exchange rates), due mainly to the following developments:

1) higher sale of CLIA products, which generated a 37.8% revenue gain in 2010;
2) a steady expansion of the installed based on Liaison analyzers, which grew to 3,641 units at December 31, 2010, thanks to 666 new placements, compared with 2,975 units at December 31, 2009;
3) market share increases in the regions where the Company has an established presence as a direct distributor, growth in markets where the sales networks of independent distributors were recently replaced by Company-operated sales networks and establishment of more effective commercial distribution agreements in some strategic areas of South America and Asia/Pacific;
4) a steadily expanding range of Liaison products, which in recent years has grown into one of the broadest menus available in the market and, most importantly, the one with the largest number of specialty tests in the fastest growing clinical segments;
5) the continuing growth of the Vitamin D market, not only in North America, but also in Europe's main countries;
6) sales of Murex products, which totaled 23.0 million euros in 2010, counting the initial inventories provided to the Abbott distributors (3.0 million euros) but net of a distribution commission of 1.4 million euros paid to Abbott.

In 2010, as was the case in previous periods, the increase in revenues translated into a proportionally larger improvement in the main profitability indicators: 2010 ended with a **gross profit** of 284.7 million euros, or 33.3% more than in 2009. This amount was equal to 70.4% of revenues, compared with 70.2% in 2009. However, it is worth noting that the sale of the initial inventory needed to distribute Murex products through Abbott had a negative impact of 0.5 percentage points over the gross profit for the year.

The increase in operating expenses was proportionally smaller than the sales gain in 2010. As a result, the ratio of operating expenses to revenues improved from 34.7% in 2009 to 32.3% in 2010.

In 2010, the Group continued to pursue a policy of investments in research and development, increasing expenditures in this area by 20.3% compared with 2009. Research and development outlays totaling 1.9 million euros were capitalized, while costs amounting to 18.6 million euros, including charges of 4.6 million euros incurred to register products marketed by the Group and comply with quality requirements, were charged directly to income.

The ratio of general and administrative expenses to revenues decreased from 10.6 percentage points in 2009 to 10.3 percentage points in 2010.

As a result, **EBIT** grew to 145.5 million euros in 2010, increasing by 36.7% compared with 2009, for a ratio of EBIT to revenues of 36.0% compared with 35.0% in 2009. **EBITDA** were 35.2% higher than in 2009, rising to 167.1 million euros, equal to 41.3% of revenues (40.7% in 2009).

Insofar as the Group's operating performance is concerned, it is worth mentioning the presence of some extraordinary items that adversely affected the results reported in 2010.

Adjustments affecting 2009 included the reclassification from operating expenses to income taxes for the year of 996 thousand euros for nondeductible tax withholdings paid by the Group's Parent Company on dividends received from its U.S. subsidiary. This reclassification produced no change in 2009 shareholders' equity and net income.

In addition, the Group recognized expenses for administrative and legal consulting services incurred in 2010 in connection with the acquisition of the Murex product line and extraordinary expenses incurred to restructure the Dartford facility (as mentioned above) for a total of 5.7 million euros. Net of these nonrecurring items, EBIT and EBITDA would be equal to 37.4% and 42.7% of revenues, respectively.

As for the Group's **financial performance,** net financial expense amounted to 585 thousand euros in 2010, compared with 2.7 million euros in 2009. The difference between these two amounts reflects primarily foreign exchange gains recognized by the Group's Parent Company on dividends received from its U.S. subsidiary. Financial expense includes 929 thousand euros in fees on factoring transactions (1.1 million euros in 2009), 810 thousand euros in interest on pension funds (868 thousand euros in 2009), 634 thousand euros in interest on borrowings owed to banks and leasing companies and gains of 296 thousand euros from the measurement at fair value of U.S. dollar forward sales contracts.

Also worth mentioning is the different accounting treatment of currency translation differences on the debt exposure denominated in U.S. dollars: following the adoption of an official foreign exchange risk management policy, the Group applies the hedge accounting principles required by IAS 39, recognizing translation differences directly in equity. In 2009, the income statement reflected foreign exchange gains of 944 thousand euros of the abovementioned indebtedness, while the translation differences recognized in equity in 2010 were negative by 1.6 million euros.

Lastly, 2010 ended with a **net profit** of 90.4 million euros, up from 70.0 million euros at the end of 2009.

It is worth noting that the Group's tax expense for 2009 amounted to 33.7 million euros (compared with 54.5 million euros in 2010), after a positive effect representing the net result of the payment of substitute taxes required to make the amortization of goodwill tax deductible and realign the differences generated upon transition to the IFRSs (4.3 million euros) and the concurrent recognition of deferred-tax assets totaling 8.9 million euros.

If the 2009 net profit were to be restated without the nonrecurring items mentioned above and the effect of the different accounting treatment of the Group's debt exposure in foreign currencies and if the 2010 result were computed without the charges for the reorganization of the U.K. factory mentioned above, the net profit for 2010 would show an increase of 43.1% compared with the previous year.

Basic **earnings per share** for 2010 amounted to 1.64 euros (1.27 euros in 2009). They were computed by dividing the Group's interest in net profit by the average number of shares outstanding, equal to 55.223 million (effect that incorporates the exercise of the first tranche of stock options awarded under the stock option plan). The stock option plan in effect at December

31, 2010 did not have a significant dilutive effect on earnings per share. In 2010, diluted earnings per share amounted to 1.64 euros.

At December 31, 2010, the **net financial position** was positive by 33.1 million euros, up from a positive balance of 11.2 million euros at the end of 2009. This improvement is mainly the result of the growing cash flow generated by the Group, which held liquid assets totaling 62.4 million euros at December 31, 2010, up from 47.9 million euros at the end of 2009.
Developments affecting the financial position in 2010 included:

- the acquisition of the Murex business operations for 46.2 million euros and the acquisition of the business operations of a local distributor by DiaSorin Australia Ltd at a price of 8.9 million Australian dollar (equal to 6.8 million euros), including 4.6 million euros payable over the next two years;
- the repayment of borrowings amounting to 8.5 million euros;
- the distribution of dividends totaling 11.0 million euros (6.6 million euros in 2009);
- increases in the Company's capital stock and additional paid-in capital by 693 thousand euros and 7.8 million euros, respectively, to implement the "2007-2012 Stock Option Plan."

Breakdown of revenues by geographic region

The table below provides a breakdown of the consolidated revenues of the DiaSorin Group by geographic region of destination. Because of the logistics flows that resulted from the need to use Abbott branches for distribution in some areas, it is currently impossible to provide an accurate breakdown of the corresponding revenues by geographic region of destination. Therefore, it seems preferable to show the revenues from sales of Murex products separately from the geographic breakdown of DiaSorin's traditional business activities. Accordingly, sales and service revenue data by geographic region are only those of DiaSorin's business activities:

(in thousands of euros)	**2010**	**2009**	**% change**
Europe and Africa	177,956	160,911	10.6%
Central and south America	25,387	18,614	36.4%
Asia/Pacific	32,943	22,600	45.8%
North America	145,236	102,004	42.4%
Total without Murex	**381,522**	**304,129**	**25.4%**
Murex	23,025	-	
Grand total	**404,547**	**304,129**	**33.0%**

Europe and Africa

In 2010, the revenues generated in Europe and Africa increased by 10.6% compared with 2009, benefitting to a limited extent from the loss of value of the euros versus the other currencies of the region, the Israeli shekel and the British pound in particular. With data at constant exchange rates, revenues shown an increase of 9.5 percentage points.

The biggest contributions to this positive performance were provided by France and Israel, with gains of 34.2% and 25.1% (+13.1% at constant exchange rates), respectively, thanks to strong demand for the Liaison Vitamin D Total test.

North America

In 2010, revenues from the North American market grew by 42.4% (+35.3% at constant exchange rates). A positive performance in the United States was matched by strong results in Canada, where revenues posted double-digit increases compared with 2009 both at current exchange rates (+36.5%) and at constant exchange rates (+29.7%).
The revenues generated in the United States benefitted not only from higher sales of Liaison Vitamin D Total tests, but also from the availability of the most complete panel of CLIA specialty tests for infectious diseases, which only DiaSorin is able to offer on the North American market. Specifically, the expansion of the customer base to include medium-sized laboratories, who are offered the possibility of combining Vitamin D tests with infectivity tests, continued successfully in 2010, with the number of infectivity customers increasing by more than 50% and 40% of new placements of Liaison systems provided with a mixed menu of infectivity and bone metabolism tests.

At December 31, 2010, revenues generated in the North American region accounted for 38.1% of the Group's total revenues (excluding sales of Murex products), up from 33.5% in 2009.

Latin America

At December 31, 2010, the cumulative revenues of the Latin American regions were up 36.4% compared with the previous year, owing in part to the appreciation of the Brazilian real versus the euro (+19.6% at constant exchange rates).

The Mexican subsidiary performed particularly well, providing a significant contribution to the region's positive performance, as it reported annual revenue that were 32.4% higher than in 2009 (+17.9% at constant exchange rates).

In the countries where the Group is not present directly, operating instead through independent distributors, annual revenues increased by 218.5% in 2010, due mainly to gains in the Venezuelan and Colombian markets.

Asia/Pacific

The revenues booked in the Asia/Pacific region totaled 32.9 million euros in 2010, for a gain of 45.8% compared with 2009 (+44.3% at constant exchange rates).
This positive performance is due in part to the August launch of a direct sales organization by the Australian subsidiary and strong sales in China, where revenues grew by 53.8 percentage points compared with 2009.

Breakdown of revenues by technology

Revenues generated by the Liaison platform continued to increase reflecting the impact of a steadily growing installed base and the Group's geographic expansion.

The table that follows shows the percentage of the Group's consolidated revenues contributed by each technology in 2010 and 2009. In order to maintain comparability with the previous year, the data in the breakdown of revenues by technology do not include sales of Murex products, which are based exclusively on ELISA technology. Had the revenues from these products been included in the breakdown by technology, the percentage of annual revenues contributed by ELISA products would have been 19.6%.

% of revenues contributed	2010	2009
RIA	5.5%	7.7%
ELISA	15.0%	19.5%
CLIA	69.9%	63.6%
Equipment sales and other revenues	9.6%	9.2%
Total without Murex	100%	100%

In 2010, the revenues generated by Liaison products showed an increase of 37.8 percentage points compared with 2009, accounting for 69.9% of total Group revenues, up from 63.6% a year earlier.

A total of 666 new Liaison analyzers were installed in 2010, increasing the installed base to 3,641 units, compared with 2,975 units at December 31, 2009. In 2010, average revenues per system amounted to about 81 thousand euros.

* * *

Andrea Alberto Senaldi, the Officer Responsible for the preparation of corporate financial reports of DiaSorin S.p.A., in accordance with the second subsection of art. 154-bis, part IV, title III, second paragraph, section V-*bis,* of Legislative Decree February 24, 1998, no. 58, declares that, to the best of his knowledge, the financial information included in the present document and enclosures corresponds to book of accounts and book-keeping entries of the Company.

DiaSorin The Diagnostic Specialist

INCOME STATEMENT OF DIASORIN S.P.A.

(in thousands of euros)	**2010**	**2009**
Sales and service revenues	174,839	143,756
Cost of sales	(97,578)	(74,109)
Gross profit	**77,261**	**69,647**
Sales and marketing expenses	(23,221)	(20,148)
Research and development costs	(10,489)	(9,465)
General and administrative expenses	(20,544)	(16,137)
Total operating expenses	**(54,254)**	**(45,750)**
nonrecurring amount	-	-
Other operating income (expense)	(5,430)	(331)
nonrecurring amount	*(5,746)*	*(1,645)*
EBIT	**17,577**	**23,566**
Net financial income (expense)	63,441	22,864
Profit before taxes	**81,018**	**46,430**
Income taxes	(11,089)	(4,590)
Net profit	**69,929**	**41,840**
Basic earnings per share	**1.27**	**0.76**
Diluted earnings per share	**1.27**	**0.76**
EBITDA(1)	**26,928**	**30,745**
	15.4%	21.4%

(1) The Company defines EBITDA as the "result from operations" before amortization of intangibles and depreciation of property, plant and equipment. EBITDA, which the Company uses to monitor and assess the Group's operating performance, are not recognized as an accounting tool in the IFRSs and, consequently, should not be viewed as an alternative gauge to assess the Group's operating performance. Because the composition of EBITDA is not governed by the reference accounting principles, the computation criterion used by the Group could be different from the criterion used by other operators and/or groups and, consequently, may not be comparable.

STATEMENT OF FINANCIAL POSITION OF DIASORIN S.P.A.

(in thousands of euros)	**12/31/10**	**12/31/09**
ASSETS		
Non-current assets		
Property, plant and equipment	24,874	17,638
Goodwill	31,851	27,591
Other intangibles	35,926	16,161
Equity investments	86,886	80,916
Deferred-tax assets	10,955	11,730
Other non-current assets	1,461	1,703
Total non-current assets	*191,953*	*155,739*
Current assets		
Inventories	41,922	32,824
Trade receivables	65,438	44,437
Loans receivables	10,173	9,894
Other current assets	2,524	3,175
Other financial assets	296	-
Cash and cash equivalents	21,786	18,607
Total current assets	142,139	108,937
TOTAL ASSETS	**334,092**	**264,676**
LIABILITIES AND SHAREHOLDERS' EQUITY		
Shareholders' equity		
Share capital	55,693	55,000
Additional paid-in capital	13,684	5,925
Statutory reserve	4,519	2,427
Other reserves	352	1,129
Translation reserve	(231)	-
Retained earnings (Loss carryforward)	70,761	40,750
Net profit for the year	69,929	41,840
Total shareholders' equity	214,707	147,071
Non-current liabilities		
Long-term borrowings	20,539	27,135
Provisions for employee severance indemnities and other employee benefits	5,666	5,606
Deferred-tax liabilities	-	-
Other non-current liabilities	1,102	919
Total non-current liabilities	27,307	33,660
Current liabilities		
Trade payables	31,934	26,301
Short-term borrowings	46,483	43,946
Other current liabilities	10,233	9,151
Income taxes payable	3,428	4,547
Total current liabilities	92,078	83,945
TOTAL LIABILITIES	119,385	117,605
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	**334,092**	**264,676**

STATEMENT OF CASH FLOWS OF DIASORIN S.P.A.

(in thousands of euros)	**2010**	**2009**
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	**18,607**	**6,933**
Net cash from operating activities	2,475	2,483
Cash used in investing activities	(13,330)	(13,035)
Cash used in Murex acquisition	(44,073)	-
Cash used in financing activities	58,107	22,226
Change in net cash and cash equivalents	***3,179***	***11,674***
CASH AND CASH EQUIVALENTS AT END OF YEAR	**21,786**	**18,607**

CONSOLIDATED INCOME STATEMENT

(in thousands of euros)	**2010**	**2009**
Sales and service revenues	404,547	304,129
Cost of sales	(119,812)	(90,484)
Gross profit	**284,735**	**213,645**
	70.4%	*70.2%*
Sales and marketing expenses	(69,818)	(56,949)
Research and development costs	(19,332)	(16,074)
General and administrative expenses	(41,702)	(32,384)
Total operating expenses	(130,852)	(105,407)
	(32.3%)	*(34.7%)*
Other operating income (expense)	(8,366)	(1,800)
nonrecurring amount	(5,746)	(1,645)
EBIT	**145,517**	**106,438**
	36.0%	*35.0%*
Net financial income (expense)	(585)	(2,705)
Profit before taxes	**144,932**	**103,733**
Income taxes	(54,514)	(33,686)
Net profit	**90,418**	**70,047**
Basic earnings per share	**1.64**	**1.27**
Diluted earnings per share	**1.64**	**1.27**
EBITDA (1)	**167,112**	**123,636**
	41.3%	*40.7%*

(1) The Company defines EBITDA as the "result from operations" before amortization of intangibles and depreciation of property, plant and equipment. EBITDA, which the Company uses to monitor and assess the Group's operating performance, are not recognized as an accounting tool in the IFRSs and, consequently, should not be viewed as an alternative gauge to assess the Group's operating performance. Because the composition of EBITDA is not governed by the reference accounting principles, the computation criterion used by the Group could be different from the criterion used by other operators and/or groups and, consequently, may not be comparable.

DiaSorin The Diagnostic Specialist

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

(in thousands of euros)	**12/31/10**	**12/31/09**
ASSETS		
Non-current assets		
Property, plant and equipment	57,551	41,963
Goodwill	65,402	59,333
Other intangibles	61,462	36,673
Equity investments	27	123
Deferred-tax assets	19,656	18,910
Other non-current assets	544	462
Total non-current assets	*204,642*	*157,464*
Current assets		
Inventories	68,311	50,331
Trade receivables	106,411	75,868
Other financial assets	296	
Other current assets	5,575	5,359
Cash and cash equivalents	62,392	47,885
Total current assets	*242,985*	179,443
TOTAL ASSETS	**447,627**	**336,907**
LIABILITIES AND SHAREHOLDERS' EQUITY		
Shareholders' equity		
Share capital	55,693	55,000
Additional paid-in capital	13,684	5,925
Statutory reserve	4,519	2,427
Other reserves	8,076	(455)
Retained earnings (Loss carryforward)	143,546	84,911
Net profit for the year	90,418	70,047
Total shareholders' equity	**315,936**	**217,855**
Non-current liabilities		
Long-term borrowings	20,799	27,862
Provisions for employee severance indemnities and other employee benefits	20,692	19,837
Deferred-tax liabilities	2,328	2,492
Other non-current liabilities	5,179	3,019
Total non-current liabilities	*48,998*	53,210
Current liabilities		
Trade payables	40,515	29,778
Other current liabilities	23,544	17,370
Income taxes payable	9,812	9,902
Current portion of long-term debt	8,822	8,792
Total current liabilities	*82,693*	65,842
Total liabilities	**131,691**	**119,052**
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	**447,627**	**336,907**

DiaSorin The Diagnostic Specialist

CONSOLIDATED STATEMENT OF CASH FLOWS

(in thousands of euros)	*2010*	*2009*
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	**47,885**	**16,790**
Net cash from operating activities	95,791	64,219
Cash used in financing activities	(7,891)	(6,332)
Cash used in investing activities	(27,156)	(26,792)
Acquisitions of subsidiaries and business operations	(46,237)	-
Change in net cash and cash equivalents	***14,507***	***31,095***
CASH AND CASH EQUIVALENTS AT END OF YEAR	**62,392**	**47,885**

About DiaSorin

DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group is comprised of 23 companies based in Europe, North, Central and South America, Africa and Asia. It has about 1,500 employees, including more than 110 research and development specialists, and operates six manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater (USA), Dublin (Ireland), Dartford (UK) and Johannesburg (SA). The last two were part of the Murex business operations, recently acquired from the Abbott Group. Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which the Group operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing.

For additional information, please visit our website: www.diasorin.it

Contacts:

Investor Relations Director
Laura Villa
DiaSorin S.p.A.
laura.villa@DiaSorin.it
+39 02 9647 4567
+39 348 15 11 542

Press Office
Carolina Mailander
c.mailander@mailander.it
+39 335 655 56 51
Bruno Caprioli
caprioli@mailander.it
+39 335 590 14 02